NASDAQ: MCRB
Seres Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$42.66M
52w High
$29.98
52w Low
$4.33
P/E
6.86
Volume
53.16K
Outstanding Shares
9.68M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 75.18% over the last year. Free cash flow grew 15.04% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -4,462.77%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases.
Valuation
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
11
Buy
3
Hold
4
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q4 FY26 · EPS est -$1.01 · Revenue est $6.35M
View